Table 2.
Patient | Age (years) | Sex | Hematological malignancy | Sample | Fungal pathogen | Antifungal resistance | History of azole exposure | Empirical antifungal treatment before identification | Treatment modification | Outcome |
---|---|---|---|---|---|---|---|---|---|---|
1 | 32 | Male | AML | Blood | Candida parapsilosis | VOR, FLC | + | CAS | – | Survived |
Blood | C. parapsilosis | VOR, FLC | + | CAS | – | Survived | ||||
Blood | C. glabrata | FLC | + | L-AmB | Central line removed | Survived | ||||
2 | 51 | Male | AML | Blood | C. parapsilosis | VOR, FLC | + | CAS | Central line removed | Survived |
Blood, wound | C. parapsilosis | VOR, FLC | + | VOR | From VOR to AmB | Died | ||||
3 | 32 | Male | AML | Blood | C. parapsilosis | VOR, FLC | + | CAS | – | Survived |
Blood | C. parapsilosis | VOR, FLC | + | VOR | From VOR to L-AmB | Survived | ||||
4 | 52 | Female | ALL | Blood | Geotrichum capitatum | FLC, ITR | − | CAS | Central line removed | Survived |
Blood | G. capitatum | FLC, ITR | + | VOR | – | Died | ||||
5 | 60 | Female | ALL | Blood | C. albicans | VOR, ITR, FLC | − | CAS | – | Survived |
6 | 21 | Female | Aplastic anemia | Blood | C. albicans | − | CAS | – | Survived | |
7 | 33 | Male | AML | Blood | G. capitatum | FLC | − | VOR | Central line removed | Survived |
8 | 55 | Female | AML | Blood | Trichosporon asahii | AmB | + | CAS | Central line removed | Died |
9 | 63 | Female | AML | Blood | T. asahii | AmB | + | L-AmB | From AmB to VOR, central line removed | Died |
10 | 45 | Female | AML | Blood | T. asahii | AmB, ITR | − | CAS | Empirically switched to VOR | Died |
11 | 50 | Male | AML + lung cancer | Blood | C. parapsilosis | + | VOR | From VOR to AmB, central line removed | Survived | |
Blood | C. albicans | + | VOR | – | Survived | |||||
12 | 62 | Female | AML | Blood, sputum | C. parapsilosis | + | VOR | From VOR to CAS, central line removed | Died | |
13 | 61 | Male | AML | Blood, urine | C. albicans | + | CAS | Died | ||
14 | 73 | Female | NHL | Blood, central line | C. albicans | + | L-AmB | Central line removed | Survived | |
15 | 35 | Male | AML | Blood | C. albicans | + | CAS | Survived | ||
16 | 44 | Female | ALL | Blood | C. albicans | + | L-AmB | Survived | ||
17 | 63 | Female | AML | Blood | C. krusei | + | VOR | – | Survived | |
18 | 51 | Female | AML | Blood | C. albicans | + | VOR | – | Survived |
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloblastic leukemia; AmB, amphotericin B; CAS, caspofungin; FLC, fluconazole; ITR, itraconazole; L-AmB, liposomal amphotericin B; NHL, non-Hodgkin lymphoma; VOR, voriconazole.